The Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) study section reviews applications that are concerned with the identification of novel antibacterial, antiparasitic, antifungal and antiviral agents for the prevention and treatment of infectious diseases and the study of the evolution, mechanisms, and transmission of drug resistance.
Note: Applications that focus on antiparasitic, antifungal, and antiviral agents are now reviewed in the Eukaryotic Pathogen and Viral Drug Discovery and Resistance (DCAI (82)) study section.
The membership panel is a list of chartered members only.
- Anti-infective drug discovery: drug target identification, characterization and validation; novel screening methods and assay development; molecular and medicinal chemical characterization of inhibitors; structure-guided drug design; preclinical studies using animal models
- Antimicrobial resistance: mechanisms and regulation of antimicrobial resistance; emergence, dissemination, and maintenance of resistance; strategies for the prevention of resistance; molecular characterization of resistant pathogens
Overlaps with Closely Related Study Sections
There are shared interests with Synthetic and Biological Chemistry A Study Section (SBCA) and Synthetic and Biological Chemistry B Study Section (SBCB) in the area of anti-infective drug development. Applications focused on the syntheses of small molecules or natural products with limited biological assessments may be reviewed in SBCA or SBCB, whereas applications involving some synthesis but more focused on the preclinical biological characterization of leads may be reviewed here.
There are shared interests with High-Throughput Screening Special Emphasis Panel (BST (55)) in the area of anti-infective drug discovery and development. Applications that focus on developing novel high-throughput screens for small molecule hits and immunotherapeutics may be reviewed in BST (55), whereas applications that focus on identifying anti-infective targets, molecular mechanisms of action, and the development of lead compounds for anti-infective therapeutics may be reviewed here.
There are shared interests with Bacterial Pathogenesis (BACP) and Host Interactions with Bacterial Pathogens (HIBP) in the area of bacterial infections and drug development. Applications that focus on general pathogenesis issues associated with bacterial infections may be reviewed in BACP or HIBP, whereas applications that focus on antimicrobial resistance mechanisms and drug discovery studies may be reviewed here.
There are shared interests with Prokaryotic Cell and Molecular Biology Study Section (PCMB) in the area of antibacterial strategies. Applications that focus on molecular mechanisms of potential bacterial drug targets may be reviewed in PCMB, whereas applications that focus on the development of antibacterial drugs may be reviewed here.
There are shared interests with Oral, Dental and Craniofacial Sciences Study Section (ODCS) in the investigation of prevention and treatment of infectious diseases. Applications that focus on identification and validation of drug targets against oral bacteria may be reviewed in ODCS, whereas applications that focus on antibacterial drug discovery may be reviewed here.